M3 Advisory Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,984
Closed -$355K 157
2024
Q3
$355K Buy
2,984
+140
+5% +$18.7K 0.26% 86
2024
Q2
$406K Buy
2,844
+507
+22% +$67.2K 0.33% 74
2024
Q1
$300K Buy
2,337
+311
+15% +$37K 0.27% 89
2023
Q4
$210K Buy
+2,026
New +$200K 0.25% 93

Other funds holding NVO

M3 Advisory Group's NVO Position: Q4 2024 in Review

M3 Advisory Group sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 2,984 shares — an estimated $355K sold.

M3 Advisory Group first reported a position in NVO in Q4 2023 and held it in 4 quarters. The position peaked at $406K in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • M3 Advisory Group reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • M3 Advisory Group sold 2,984 Novo Nordisk shares in Q4 2024, an estimated $355K.
  • M3 Advisory Group first reported a position in Novo Nordisk in Q4 2023 and held it in 4 quarters.
  • M3 Advisory Group's Novo Nordisk position peaked at $406K in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on M3 Advisory Group's 13F filing for Q4 2024, filed 21 Jan 2025.